期刊文献+

无偿献血者血管性血友病因子的含量及临床意义

The Levels of vWF in the Plasma of Voluntary Blood Donors and its Clinical Significance
暂未订购
导出
摘要 目的通过检测献血者血浆中血管性血友病因子(vWF),为其制备冷沉淀和临床应用提供依据。方法应用酶联免疫吸附法检测无偿献血者血浆和普通冰冻血浆中vWF含量。结果无偿献血者血浆中vWF含量为(125.81±48.71)%,去冷沉淀血浆中含量为(25.52±9.29)%。结论无偿献血者血液采集后6h内分离的血浆,其vWF含量稳定,可用于冷沉淀制备和临床应用。 Objective The yon Willebrand Factor (vWF) in the plasma of voluntary blood donors was detected, for the purpose to provide evidence for its clinical application and producing of cryoprecipitate. Methods The concentrations of vWF in fresh plasma and cryoprecipitate reduced plasma were determined by enzyme linked-immuno-sorbent assay. Re- suits The levels of vWF in the fresh and ordinary frozen plasma were (125.81±48.71)% and (25.52±9.29) respec- tively. Conclusion The vWF in the donated blood is stable within 6 hours. The plasma is qualified for vWF supplement and producing cryoprecipitate.
出处 《临床输血与检验》 CAS 2012年第4期297-298,共2页 Journal of Clinical Transfusion and Laboratory Medicine
基金 南京军区南京总医院科研基金(No.2011048) 南京军区医学科技创新重点项目(No.11Z026)资助
关键词 血管性血友病因子 无偿献血者 冷沉淀 普通冰冻血浆 Von Willebrand Factor Voluntary blood donors Cryoprecipitate Ordinary frozen plasma
  • 相关文献

参考文献7

  • 1Howman R, Barnes C,Curtin J ,et al. The clinical effica- cy and safety of the F Ⅵ/VWF concentrate, BIOSTATE, in children with von Willebrand disorder: a multi-centre retrospective review [J]. Haemophilia, 2011, 17(3) :463-469.
  • 2Federici AB,Barillari G,Zanon E, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited yon Willebrand' s disease: results of an Italian cohort study on 120 pa- tients characterized by bleeding severity score [J]. Haemophilia, 2010, 16(1) : 101-110.
  • 3Nieswandt B,Stoll G. The smaller, the better: VWF in stroke[J]. Blood, 2010, 115(8) : 1477-1478.
  • 4林昂.去冷沉淀血浆部分凝血因子及蛋白含量的研究[J].临床输血与检验,2011,13(2):149-150. 被引量:10
  • 5袁忠海,赵军,张英,朱平.vWF基因A1381T多态性和ABO血型对血浆vWF水平的影响[J].中国实验血液学杂志,2010,18(4):967-971. 被引量:10
  • 6Klukowska A, Windyga J, I3atorova A. Clinical effica- cy of a novel VWF-containing F Ⅵ concentrate, Wilate, in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients [J]. Thromb Res, 2011, 127(3):247-253.
  • 7Bowyer AE, Shepherd F, Kitchen S, et al. A rapid automated VWF ristocetin cofactor activity assay im- proves reliability in the diagnosis of Von Villehrand disease [J]. Thromb Res, 2011, 127(4): 341-344.

二级参考文献18

  • 1Klemm T, Mehnert AK, Siegemund A, et al. Impact of the Thr789Ala variant of the von Willebrand factor levels , on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes, 2005 ; 113 (10) :568 - 572.
  • 2Keightley AM, Lain YM, Brady Willebrand factor (vWF) gene JN, et al. Variation at the yon locus is associated with plasma vWF: Ag levels :identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood, 1999 ; 93 ( 12 ) : 4277 - 4283.
  • 3Harvey PJ, Keighfley AM, Lam YM, et al. A single nucleotide polymorphism at nncleotide 1793 in the von Willebrand factor (vWF) regulatory region is associated with plasma vWF: Ag levels. Br J Haematol, 2000;109(2) :349 -353.
  • 4Simon D, Palatnikb M, Roisenberga I. Analysis of the-1185A/G yon Willebrand factor (vWF) gene polymorphism in two Brazilian ethnic groups and its effect on the plasma vWF levels. Thromb Res, 2002;105(6) :519 -522.
  • 5Davies JA, Collins PW, Hathaway LS, et al. Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood ,2007;109 (7) :2840 - 2846.
  • 6Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost, 2003 ; 1 ( 1 ) :33 -40.
  • 7Shima M, Fujimura Y, Nishiyama T, et al. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang, 1995 ;68(4) :236 -240.
  • 8Davies JA, Collins PW, Hathaway LS, et al. von Willebrand factor: evidence for variable clearance in vivo according to Y/ C1584 phenotype and ABO blood group. J Thromb Haemost, 2008;6( 1 ) :97 - 103.
  • 9Simon D, Paludo CA, Ghisleni GC, et al. Association studies between -1185A/G von Willebrand factor gene polymorphism and coronary artery disease. Braz J Med Biol Res, 2003 ;36 (6) :709 - 714.
  • 10Lip GY, Blann A. von Willebrand factor : a marker of endothelial dysfunction in vascular disorder? Cardiovasc Res, 1997 ; 34 ( 2 ) : 255 - 265.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部